CONMED CORPORATION Goodwill, Subsequent Recognition of Deferred Tax Asset
CONMED CORPORATION (CNMD) reported Goodwill, Subsequent Recognition of Deferred Tax Asset of $9.00 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-02-18.
Financial Statements › Notes › Goodwill and Other
us-gaap:GoodwillSubsequentRecognitionOfDeferredTaxAsset · last filed 2025-02-18
- CONMED CORPORATION goodwill, subsequent recognition of deferred tax asset for fiscal 2023 was $9.00M.
| Period end | Goodwill, Subsequent Recognition of Deferred Tax Asset 12 month |
|---|---|
| 2023-12-31 | $9.00M 10-K · filed 2025-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Neuraxis, INC (NRXS) | United States | $0.097B |